Streetbeat News

FWBI

First Wave BioPharma Inc

https://www.azurrx.com/

CEO

James Sapirstein

Employees

Industry

Research and Development in Biotechnology (except Nanobiotechnology)

azurrx biopharma aims to become a leader in developing non-systemic, recombinant protein therapies for the treatment of gastrointestinal diseases and related conditions. ms1819 recombinant lipase for exocrine pancreatic insufficiency is the lead development program with additional early stage research being conducted for the prevention of hospital-acquired infection. the company is headquartered in new york, ny, with scientific operations based in langlade, france.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

In Monday's pre-market session, several healthcare stocks showed significant movement. Quoin Pharmaceuticals, Ainos, and Helius Medical Tech were among the top gainers, with stock prices increasing by 71.1%, 69.52%, and 55.04% respectively. On the losing side, BioVie, First Wave BioPharma, and Sunshine Biopharma saw declines of 46.0%, 29.44%, and 21.49%. Notably, 89bio and Akili released their Q4 earnings reports two days ago, influencing their stock movements.

Portfolio Pulse from Benzinga Insights

March 04, 2024 | 1:09 pm

First Wave BioPharma, Inc. (NASDAQ:FWBI) announced a registered direct offering of 525,625 shares at $7.61 per share, aiming to raise approximately $4M. Additionally, the company will issue warrants for the same number of shares at $7.48 per share in a private placement. Roth Capital Partners is the placement agent. The proceeds will be used for working capital and general corporate purposes, with the offering's closing expected around March 6, 2024.

Portfolio Pulse from Benzinga Newsdesk

March 04, 2024 | 1:03 pm

Mobileye Global Inc. (MBLY) shares plummeted over 23% after issuing preliminary FY23 financial results and initial 2024 guidance, which were below the previous implied guidance. Wolfe Research analyst Shreyas Patil downgraded the stock from Outperform to Peer Perform. Other stocks experienced significant movement in Thursday's mid-day session, with various companies reporting gains due to positive developments, collaborations, and strategic reviews, while others faced declines due to public offerings, corporate updates, and preliminary financial results.

Portfolio Pulse from Avi Kapoor

January 04, 2024 | 6:37 pm

Resources Connection, Inc. (NASDAQ:RGP) shares increased by over 6% in pre-market trading due to Q2 earnings of 28 cents per share, surpassing estimates of 18 cents, and sales of $163.1 million, beating expectations of $161.936 million. Other stocks experienced pre-market movements, with notable gainers including Jeffs' Brands Ltd (NASDAQ:JFBR), Kintara Therapeutics, Inc. (NASDAQ:KTRA), and The Arena Group Holdings, Inc. (NYSE:AREN), while significant losers were SELLAS Life Sciences Group, Inc. (NASDAQ:SLS), Hallmark Financial Services, Inc. (NASDAQ:HALL), and Cal-Maine Foods, Inc. (NASDAQ:CALM) due to various company-specific news and analyst actions.

Portfolio Pulse from Avi Kapoor

January 04, 2024 | 12:59 pm

First Wave BioPharma, Inc. (NASDAQ:FWBI) shares surged after the company announced a non-binding agreement to sell its niclosamide program for inflammatory bowel diseases, with a low seven-figure upfront payment, future milestones, and royalties. The deal is expected to close in the first half of 2024. Additionally, FWBI will acquire ImmunogenX in an all-stock transaction, focusing on advancing a GI pipeline with late-stage clinical assets, also expected to close in the first half of 2024. The company recently underwent a 1-for-20 reverse stock split.

Portfolio Pulse from Erica Kollmann

January 03, 2024 | 8:21 pm

First Wave BioPharma's stock (FWBI) is trading higher following Roth MKM's decision to maintain a Buy rating and increase the price target from $11 to $40.

Portfolio Pulse from Benzinga Newsdesk

January 03, 2024 | 7:12 pm

Roth MKM analyst Jonathan Aschoff has maintained a Buy rating on First Wave BioPharma (NASDAQ:FWBI) and increased the price target from $11 to $40. This significant adjustment reflects a positive outlook on the company's prospects.

Portfolio Pulse from Benzinga Newsdesk

January 03, 2024 | 6:16 pm

SoFi Technologies, Inc. (SOFI) shares dropped by approximately 13% after Keefe, Bruyette & Woods downgraded the stock from Market Perform to Underperform and reduced the price target from $7.50 to $6.50. The downgrade was based on recent outperformance and changes in the analyst's model. Other stocks experienced significant movements in Wednesday's mid-day session, with various companies reporting gains due to positive developments such as regulatory approvals, partnership announcements, and favorable analyst ratings. Conversely, some stocks saw declines due to negative news such as poor earnings, strategic setbacks, or unfavorable analyst actions.

Portfolio Pulse from Avi Kapoor

January 03, 2024 | 5:58 pm

In Wednesday's intraday session, several healthcare stocks experienced significant movements. NexImmune (NEXI) saw a substantial increase of 230.5%, while ABVC BioPharma (ABVC) and First Wave BioPharma (FWBI) also posted notable gains. Conversely, Nemaura Medical (NMRD), TC BioPharm (TCBP), and Esperion Therapeutics (ESPR) were among the stocks that declined. These movements reflect the volatility and rapid changes in the healthcare sector, impacting the market value of these companies.

Portfolio Pulse from Benzinga Insights

January 03, 2024 | 5:31 pm

First Wave BioPharma, Inc. shares have resumed trading after a temporary halt.

Portfolio Pulse from Benzinga Newsdesk

January 03, 2024 | 2:39 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.